default author photo

Angelique Richardson

affiliation not provided to SSRN

SCHOLARLY PAPERS

1

DOWNLOADS

28

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Higher serum activin A predicts adverse outcomes in AI-refractory hormone receptor-positive metastatic breast cancer in the Phase III BOLERO-2 trial (everolimus + exemestane vs exemestane alone)

Number of pages: 18 Posted: 25 Mar 2026
affiliation not provided to SSRN, Thomas Jefferson University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, Pennsylvania State University - Penn State Hershey Medical Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Pennsylvania State University - Penn State Hershey Medical Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - MD Anderson Cancer Center, affiliation not provided to SSRN and Pennsylvania State University - Penn State Hershey Medical Center
Downloads 28 (1,385,945)

Abstract:

Loading...

Biomarkers, metastatic breast cancer, hormone receptor positive, serum activin A